ribosomal protein L11Genealiases: DBA7 · GIG34 · L11 · uL5
Q-omics provides the consensus-scored RPL11 profile across patient tissues and cancer cell-line models. RPL11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL11 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL11 protein abundance shows 28,950 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPL11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL11 survival associations across molecular data types. RPL11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL11 RNA expression–survival associations across cancer types. High RPL11 expression shows unfavorable associations in ACC, LIHC, CESC, KICH, SCLC and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL11 RNA expression.
This table summarizes RPL11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL11 shows lower tumor expression in LUAD, BRCA and KICH and higher tumor expression in KIRC, COAD and LIHC. The KIRC box plot shows higher RPL11 RNA expression in tumor versus normal tissue (log2 FC = +0.942, t-test p < 0.001).
This table shows molecular features associated with RPL11 in patient tissues and cancer cell lines. In patient samples, RPL11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
